

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 16, 2017**

---

**Tandem Diabetes Care, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36189**  
(Commission  
File Number)

**20-4327508**  
(I.R.S. Employer  
Identification No.)

**11045 Roselle Street, San Diego, CA**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 366-6900**

**N/A**

**(Former name or former address, if changed since last report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Our Annual Meeting of Stockholders was held on May 16, 2017 (the "Annual Meeting"). We had 49,836,070 shares of common stock outstanding on March 28, 2017, the record date for the Annual Meeting. At the Annual Meeting, 41,859,984 shares of common stock were present in person or represented by proxy. The following sets forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in our definitive proxy statement, dated April 6, 2017.

Proposal 1: Election of three members of the Board of Directors of the Company. The shareholders elected three directors to hold office until the 2020 Annual Meeting of Stockholders, or until their successors are duly elected and qualified, by the following votes:

<b>Name of Director Elected</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Kim D. Blickenstaff	26,772,905	1,355,205	13,731,874
Howard E. Greene, Jr.	26,726,965	1,401,145	13,731,874
Christopher J. Twomey	26,812,646	1,315,464	13,731,874

Proposal 2: Ratification of the appointment of Ernst & Young LLP to serve as the independent registered public accountant for the 2017 fiscal year. The proposal was approved, by the following vote:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
41,643,496	197,477	19,011	—

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

/s/ David B. Berger

David B. Berger

Executive Vice President, General Counsel and Secretary

Date: May 18, 2017